Roth Capital Downgrades CardioNet (BEAT) to Hold
More News related to BEAT
- CardioNet, Inc. Reports Third Quarter 2009 Financial Results
- CardioNet (BEAT) Updates Mobile Cardio Telemetry Reimbursement Info
- CardioNet, Inc. Provides Update on Mobile Cardiovascular Telemetry Reimbursement
- CardioNet (BEAT) Approved for 15th U.S. Patent
- CardioNet Awarded its 15th U.S. Patent
Roth Capital downgrades CardioNet (Nasdaq: BEAT) from Buy to Hold. Price target slashed from $29 to $18.
To see more analyst ratings on BEAT Click Here.
CardioNet, Inc. provides ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual's health in the United States.
Related Categories
DowngradesStocks Mentioned
-0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
